Open AccessFOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Author(s) -
Jean-Florian Guion-Dusserre,
Véronique Lorgis,
Julie Vincent,
Leila Bengrine,
François Ghiringhelli
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i7.2096
Subject(s) - folfiri , medicine , bevacizumab , irinotecan , folinic acid , gastroenterology , chemotherapy , fluorouracil , response evaluation criteria in solid tumors , regimen , chemotherapy regimen , surgery , progressive disease , colorectal cancer , cancer
To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for metastatic intrahepatic cholangiocarcinoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom